Noah Schlachter, Eben Lichtman, Adam Palmer. "Daratumumab provides equivalent survival benefits in first-line and second-line treatment of transplant-ineligible multiple myeloma: A computational analysis of Phase 3 trials in first-line and second-line settings.." Blood, 2025. doi:10.1182/blood-2025-4011